Journal articles on the topic 'Imidy'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Imidy.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Dunbar, Karen, Thomas J. Macartney, and Gopal P. Sapkota. "IMiDs induce FAM83F degradation via an interaction with CK1α to attenuate Wnt signalling." Life Science Alliance 4, no. 2 (December 23, 2020): e202000804. http://dx.doi.org/10.26508/lsa.202000804.
Full textYang, Seung-Joo, Seungje Jeon, Jeong Won Baek, Kwang Min Lee, and Chul-Seung Park. "Regulation of AMPK Activity by CRBN Is Independent of the Thalidomide-CRL4CRBN Protein Degradation Axis." Pharmaceuticals 14, no. 6 (May 26, 2021): 512. http://dx.doi.org/10.3390/ph14060512.
Full textCostacurta, Matteo, Jackson He, Philip E. Thompson, and Jake Shortt. "Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy." Journal of Personalized Medicine 11, no. 11 (November 11, 2021): 1185. http://dx.doi.org/10.3390/jpm11111185.
Full textTochigi, Taro, Toshihiro Miyamoto, Kiwamu Hatakeyama, Teppei Sakoda, Daisuke Ishihara, Hidetoshi Irifune, Takahiro Shima, et al. "Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug–induced thrombocytopenia." Blood 135, no. 24 (June 11, 2020): 2146–58. http://dx.doi.org/10.1182/blood.2019003749.
Full textXu, Yibing, JianWu Li, Greg Ferguson, Frank Mercurio, Gody Khambatta, Lisa Morrison, Antonia Lopez-Girona, et al. "Identification of Novel Activities of Immunomodulatory Drugs: Cytoskeleton Reorganization through Modulation of Rho GTPases." Blood 112, no. 11 (November 16, 2008): 2565. http://dx.doi.org/10.1182/blood.v112.11.2565.2565.
Full textFiroozmand, Amin, Naveed Ali, Nausheen Ahmed, Pingfu Fu, Shufen Cao, George Brown, Hannah Schmikla, et al. "A highly effective and practical desensitization regimen: Results in comparable clinical outcomes for multiple myeloma patients with skin rash after immunomodulatory drugs." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 12104. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.12104.
Full textCaracciolo, Daniele, Caterina Riillo, Giada Juli, Francesca Scionti, Katia Todoerti, Nicoletta Polerà, Katia Grillone, et al. "miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma." Cancers 13, no. 17 (August 29, 2021): 4365. http://dx.doi.org/10.3390/cancers13174365.
Full textGemechu, Yohannes, David Millrine, Shigeru Hashimoto, Jaya Prakash, Ksenia Sanchenkova, Hozaifa Metwally, Parajuli Gyanu, Sujin Kang, and Tadamitsu Kishimoto. "Humanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs." Proceedings of the National Academy of Sciences 115, no. 46 (October 29, 2018): 11802–7. http://dx.doi.org/10.1073/pnas.1814446115.
Full textCoto, Pablo, Sabino Riestra, Paloma Rozas, Ana Señaris, and Rubén Queiro. "Improving the standard of care for patients with spondyloarthritis-related immune inflammatory conditions: results of a Delphi study and proposal for early detection." Therapeutic Advances in Chronic Disease 11 (January 2020): 204062232090429. http://dx.doi.org/10.1177/2040622320904295.
Full textOlszewski, Adam J., Stacie Dusetzina, Amy J. Davidoff, and Amal N. Trivedi. "Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents." Journal of Clinical Oncology 35, no. 15_suppl (May 20, 2017): 6522. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.6522.
Full textCharliński, Grzegorz, David H. Vesole, and Artur Jurczyszyn. "Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma." Cancers 13, no. 18 (September 17, 2021): 4666. http://dx.doi.org/10.3390/cancers13184666.
Full textHeider, Michael, Ruth Eichner, Jacob Stroh, Anna Kuisl, Jana Zecha, Jannis Lawatscheck, Martina Rudelius, et al. "The IMiD-Target Cereblon Determines Transmembrane Protein Quality Control Promoting Tumor Metabolism." Blood 134, Supplement_1 (November 13, 2019): 314. http://dx.doi.org/10.1182/blood-2019-129064.
Full textDimopoulos, Konstantinos, Peter Gimsing, Gangning Liang, Kirsten Grønbæk, Alexandra Helbo Søgaard, and Ranjani Lakshminarasinham. "Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy." Blood 128, no. 22 (December 2, 2016): 3258. http://dx.doi.org/10.1182/blood.v128.22.3258.3258.
Full textOlszewski, Adam J., Stacie B. Dusetzina, Charles B. Eaton, Amy J. Davidoff, and Amal N. Trivedi. "Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma." Journal of Clinical Oncology 35, no. 29 (October 10, 2017): 3306–14. http://dx.doi.org/10.1200/jco.2017.72.2447.
Full textGavriatopoulou, Maria, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, et al. "IMiD Retreatment in Patients Refractory to Both an IMiD and an Anti-CD38 Antibody Induces Significant Response Rates Post Anti-CD38 Exposure." Blood 136, Supplement 1 (November 5, 2020): 12. http://dx.doi.org/10.1182/blood-2020-136248.
Full textRomero-Jimenez, Rosa, Vicente Escudero-Vilaplana, Esther Chamorro-De-Vega, Arantza Ais-Larisgoitia, Maria Elena Lobato Matilla, Ana Herranz-Alonso, and Maria Sanjurjo. "The Characteristics and Functionalities of Mobile Apps Aimed at Patients Diagnosed With Immune-Mediated Inflammatory Diseases: Systematic App Search." Journal of Medical Internet Research 24, no. 3 (March 4, 2022): e31016. http://dx.doi.org/10.2196/31016.
Full textLai, Edward Chia-Cheng, Ya-Chun Huang, Tzu-Chi Liao, and Meng-Yu Weng. "Premature coronary artery disease in patients with immune-mediated inflammatory disease: a population-based study." RMD Open 8, no. 1 (January 2022): e001993. http://dx.doi.org/10.1136/rmdopen-2021-001993.
Full textNadeau Nguyen, Michelle, Afrouz Nayernama, Steven Christopher Jones, Yvette L. Kasamon, and Peter E. Waldron. "Solid Organ Transplant Rejection Associated with the Use of the Immunomodulatory Drugs (IMIDs)." Blood 134, Supplement_1 (November 13, 2019): 2189. http://dx.doi.org/10.1182/blood-2019-123146.
Full textMillrine, David, Mami Tei, Yohannes Gemechu, and Tadamitsu Kishimoto. "Rabex-5 is a lenalidomide target molecule that negatively regulates TLR-induced type 1 IFN production." Proceedings of the National Academy of Sciences 113, no. 38 (September 6, 2016): 10625–30. http://dx.doi.org/10.1073/pnas.1611751113.
Full textLiu, Jiye, Teru Hideshima, Lijie Xing, Su Wang, Wenrong Zhou, Mehmet K. Samur, Tomasz Sewastianik, et al. "ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment." Science Advances 7, no. 23 (June 2021): eabg2697. http://dx.doi.org/10.1126/sciadv.abg2697.
Full textHaberman, Rebecca H., Ramin Herati, David Simon, Marie Samanovic, Rebecca B. Blank, Michael Tuen, Sergei B. Koralov, et al. "Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease." Annals of the Rheumatic Diseases 80, no. 10 (May 25, 2021): 1339–44. http://dx.doi.org/10.1136/annrheumdis-2021-220597.
Full textVij, Ravi, Mehdi M. Moezi, Robin Foà, Gordon Cook, Antonio Palumbo, Hakan Kaya, Brian Durie, et al. "A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study." Blood 122, no. 21 (November 15, 2013): 1964. http://dx.doi.org/10.1182/blood.v122.21.1964.1964.
Full textTascilar, K., D. Simon, G. Krönke, A. Kleyer, A. Ramming, R. Atreya, M. Tenbusch, et al. "POS1426 PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES ARE OVERREPRESENTED IN LOW- FREQUENCY VIRAL SYMPTOM CLUSTERS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 996.2–997. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1598.
Full textPark, Isaac, Tra Mi Phan, and Jing Fang. "Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q." Cancers 13, no. 20 (October 11, 2021): 5084. http://dx.doi.org/10.3390/cancers13205084.
Full textHuang, Xiangao, David Jayabalan, Maurizio Di Liberto, Zhengming Chen, Anna C. Schinzel, Scott Ely, Adriana C. Rossi, et al. "Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation." Blood 126, no. 23 (December 3, 2015): 500. http://dx.doi.org/10.1182/blood.v126.23.500.500.
Full textWelsh, Seth, Daniel Riggs, Erin Meermeier, Chang-Xin Shi, Victoria Garbitt, Meaghen E. Sharik, Megan Du, et al. "Disrupting Ectopic Super-Enhancers to Treat Multiple Myeloma." Blood 138, Supplement 1 (November 5, 2021): 1593. http://dx.doi.org/10.1182/blood-2021-147551.
Full textPatil, Ajinkya, Mark Manzano, and Eva Gottwein. "CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma." Blood 132, no. 6 (August 9, 2018): 577–86. http://dx.doi.org/10.1182/blood-2018-01-828418.
Full textSuska, Anna, Maciej Rafał Czerniuk, and Artur Jurczyszyn. "Next-generation immunomodulatory drugs in multiple myeloma." Postępy Higieny i Medycyny Doświadczalnej 73 (December 31, 2019): 791–802. http://dx.doi.org/10.5604/01.3001.0013.6907.
Full textSimon, David, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, Raja Atreya, et al. "SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases." Annals of the Rheumatic Diseases 80, no. 10 (May 6, 2021): 1312–16. http://dx.doi.org/10.1136/annrheumdis-2021-220461.
Full textDavis, Lorraine, Zachary J. Walker, Denis Ohlstrom, Brett M. Stevens, Peter A. Forsberg, Tomer M. Mark, Craig T. Jordan, and Daniel W. Sherbenou. "309 MYC Inhibition Overcomes IMiD Resistance in Heterogeneous Multiple Myeloma Populations." Journal of Clinical and Translational Science 6, s1 (April 2022): 54. http://dx.doi.org/10.1017/cts.2022.169.
Full textMadan, Sumit, Martha Q. Lacy, Angela Dispenzieri, Morie A. Gertz, Francis Buadi, Suzanne R. Hayman, Kristen Detweiler-Short, et al. "Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma." Blood 118, no. 7 (August 18, 2011): 1763–65. http://dx.doi.org/10.1182/blood-2011-04-350009.
Full textGarcillán, Beatriz, Miguel Salavert, José R. Regueiro, and Sabela Díaz-Castroverde. "Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review." Vaccines 10, no. 2 (February 15, 2022): 297. http://dx.doi.org/10.3390/vaccines10020297.
Full textBarankiewicz, Joanna, Anna Szumera-Ciećkiewicz, Aleksander Salomon-Perzyński, Paulina Wieszczy, Agata Malenda, Filip Garbicz, Monika Prochorec-Sobieszek, Irena Misiewicz-Krzemińska, Przemysław Juszczyński, and Ewa Lech-Marańda. "The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients." Journal of Clinical Medicine 10, no. 12 (June 18, 2021): 2683. http://dx.doi.org/10.3390/jcm10122683.
Full textRundgren, Ida Marie, Anita Ryningen, Tor Henrik Anderson Tvedt, Øystein Bruserud, and Elisabeth Ersvær. "Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes." Molecules 25, no. 2 (January 16, 2020): 367. http://dx.doi.org/10.3390/molecules25020367.
Full textLeBlanc, Richard, Teru Hideshima, Laurence P. Catley, Reshma Shringarpure, Renate Burger, Nicholas Mitsiades, Constantine Mitsiades, et al. "Immunomodulatory drug costimulates T cells via the B7-CD28 pathway." Blood 103, no. 5 (March 1, 2004): 1787–90. http://dx.doi.org/10.1182/blood-2003-02-0361.
Full textOtt, Christopher J., Gang Lu, Jaime Reyes, Charles Y. Lin, William G. Kaelin, and James E. Bradner. "Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents." Blood 124, no. 21 (December 6, 2014): 420. http://dx.doi.org/10.1182/blood.v124.21.420.420.
Full textPal, Rekha, Sara A. Monaghan, Andrea Cortese Hassett, Markus Y. Mapara, Peter Schafer, G. David Roodman, Margaret V. Ragni, Lynn Moscinski, Alan List, and Suzanne Lentzsch. "Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia." Blood 115, no. 3 (January 21, 2010): 605–14. http://dx.doi.org/10.1182/blood-2009-05-221077.
Full textManic, Marina S., and Vesna Najdanovic-Visak. "Solubility of Mixtures Containing Soybean Oil, Ionic Liquid and Methanol." Open Chemical Engineering Journal 10, no. 1 (April 8, 2016): 41–49. http://dx.doi.org/10.2174/1874123101610010041.
Full textLindner, Stefanie, Christian Steinebach, Namrata Udeshi, Deepak Mani, Hannes Kehm, Simon Köpff, Steven A. Carr, Michael Gütschow, and Jan Krönke. "Pomalidomide-Based Homo-Protacs for the Chemical Knockdown of Cereblon." Blood 132, Supplement 1 (November 29, 2018): 260. http://dx.doi.org/10.1182/blood-2018-99-116376.
Full textKimpton, Miriam, Ryan Buyting, Daniel J. Corsi, Natasha Rupani, Marc Carrier, and Arleigh McCurdy. "Incidence and Risk Factors of Venous Thromboembolism in Patients with Multiple Myeloma Receiving Immunomodulatory Agents." Blood 128, no. 22 (December 2, 2016): 2624. http://dx.doi.org/10.1182/blood.v128.22.2624.2624.
Full textMan, Louise, Amy L. Morris, Jacqueline Brown, Surabhi Palkimas, and Kelly Mercer Davidson. "Use of Direct Oral Anticoagulants in Patients on Immunomodulatory Agents." Blood 128, no. 22 (December 2, 2016): 1449. http://dx.doi.org/10.1182/blood.v128.22.1449.1449.
Full textChirackal, Sinto Sebastian, Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi, Sonali Panchabhai, Gregory Ahmann, Scott A. Van Wier, et al. "Immunomodulatory Drugs Inhibit H2O2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity." Blood 126, no. 23 (December 3, 2015): 2475. http://dx.doi.org/10.1182/blood.v126.23.2475.2475.
Full textFotiou, Despina, Ioannis V. Kostopoulos, Maria Krevvata, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Pantelis Roussakis, Chrysanthi Panteli, et al. "Evaluation of Efficacy and Immune Modulation Associated with the Addition of IMiDs to Daratumumab Backbone in Patients Refractory to Both Drug Classes." Blood 138, Supplement 1 (November 5, 2021): 1668. http://dx.doi.org/10.1182/blood-2021-150032.
Full textJakobsen, Theresa, Mette Dahl, Konstantinos Dimopoulos, Kirsten Grønbæk, Jørgen Kjems, and Lasse Sommer Kristensen. "Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells." Cancers 13, no. 3 (January 20, 2021): 365. http://dx.doi.org/10.3390/cancers13030365.
Full textCuddihy, Andrew R., Parisa Asvadi, Rosanne Dunn, Tiffany T. Khong, and Andrew Spencer. "The Anti-Kappa Monoclonal Antibody MDX-1097 Synergizes with Immunomodulatory Drugs to Enhance Antibody-Dependent Cell Cytotoxicity of Multiple Myeloma Cells." Blood 120, no. 21 (November 16, 2012): 4012. http://dx.doi.org/10.1182/blood.v120.21.4012.4012.
Full textVolkers, A., L. Wieske, K. van Dam, M. Steenhuis, E. Stalman, L. Kummer, Z. van Kempen, et al. "DOP27 Humoral immune response after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases treated with immunosuppressive therapy - a Target to B! study." Journal of Crohn's and Colitis 16, Supplement_1 (January 1, 2022): i079. http://dx.doi.org/10.1093/ecco-jcc/jjab232.066.
Full textDennert, Robert, Pieter van Paassen, Petra Wolffs, Catrien Bruggeman, Sebastiaan Velthuis, Susanne Felix, Robert-Jan van Suylen, Harry J. Crijns, Jan Willem Cohen Tervaert, and Stephane Heymans. "Differences in Virus Prevalence and Load in the Hearts of Patients with Idiopathic Dilated Cardiomyopathy with and without Immune-Mediated Inflammatory Diseases." Clinical and Vaccine Immunology 19, no. 8 (June 13, 2012): 1182–87. http://dx.doi.org/10.1128/cvi.00281-12.
Full textLi, Ang, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman, and Kristen M. Sanfilippo. "Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma." Journal of the National Comprehensive Cancer Network 17, no. 7 (July 2019): 840–47. http://dx.doi.org/10.6004/jnccn.2018.7273.
Full textFiroozmand, Amin, Naveed Ali, Nausheen Ahmed, Pingfu Fu, Shufen Cao, George Brown, Hannah Schmikla, et al. "Low Dose Daily Corticosteroid Tapering Regimen Allows Highly Effective and Practical Desensitization for Multiple Myeloma Patients with Skin Rash after Immunomodulatory Drugs." Blood 136, Supplement 1 (November 5, 2020): 19–20. http://dx.doi.org/10.1182/blood-2020-140800.
Full textGalloway, James, Kevin Barrett, Peter Irving, Kaivan Khavandi, Monica Nijher, Ruth Nicholson, Simon de Lusignan, and Maya H. Buch. "Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study." RMD Open 6, no. 3 (September 2020): e001392. http://dx.doi.org/10.1136/rmdopen-2020-001392.
Full text